Imagine discovering a hidden weakness in a dangerous virus that could revolutionize how we fight it — this is the exciting breakthrough currently unfolding with the monkeypox virus, thanks to the power of artificial intelligence (AI). An international team of scientists has taken a significant early step toward developing more effective and accessible vaccines or antibody-based treatments against MPXV, the virus responsible for monkeypox. The implications of this research are profound, especially considering the severe symptoms and high mortality rate associated with the virus, which mainly threaten children, pregnant women, and individuals with weakened immune systems.
In a detailed study published in Science Translational Medicine, researchers revealed that mice vaccinated with a specific viral surface protein — identified through innovative AI analysis — produced potent neutralizing antibodies. This promising discovery points to a new strategic direction for designing future monkeypox vaccines and therapies, potentially overcoming many challenges posed by traditional methods.
In the 2022 outbreak, monkeypox made headlines globally, infecting over 150,000 people across many countries. Symptoms ranged from flu-like illness to noticeable rashes and skin lesions, with nearly 500 fatalities reported. To mitigate the outbreak, health authorities relied on existing smallpox vaccines, which, while somewhat effective, have major drawbacks: they are costly, complex to produce, and require handling a live virus, raising safety concerns.
"Compared to complex, whole-virus vaccines, our approach simplifies everything by focusing on just a single protein that's straightforward to manufacture," explained Dr. Jason McLellan, a molecular biosciences professor at The University of Texas at Austin and a leading author of the study.
The researchers didn't stop there. Alongside colleagues Rino Rappuoli and Emanuele Andreano from Italy’s Fondazione Biotecnopolo di Siena, they identified 12 specific antibodies from the blood of individuals who had either recovered from monkeypox or been vaccinated against it. These antibodies demonstrated strong neutralizing activity against the virus. However, what remained unclear was the precise part of the virus each antibody targeted — a critical piece of the puzzle in designing new, more effective treatments.
Monkeypox’s surface harbors numerous proteins, at least one of which is vital for spreading the infection within host cells. The team knew some antibodies could block this process — but they didn't yet know which surface protein was the key. To unravel this mystery, they needed to identify the exact viral component—called an antigen—that the antibodies recognized.
Here’s where AI truly shined. Using a breakthrough model called AlphaFold 3, the team predicted which of roughly 35 surface proteins on MPXV would strongly interact with the antibodies. The analysis pointed toward a previously overlooked protein named OPG153. Laboratory experiments then confirmed this prediction, showing OPG153 was indeed the prime target for neutralizing antibodies. This discovery opens up new frontiers — OPG153 could serve as the core element in future vaccines or antibody treatments that help the immune system recognize and fight monkeypox more effectively.
"Without AI, it would have taken years to pinpoint this target," McLellan emphasized. "It was an exciting moment, especially since no one had ever considered OPG153 as a vaccine or antibody target before. This opens up entirely new avenues for therapy development." Because monkeypox shares close similarities with the smallpox virus — which also utilizes similar proteins to infect humans — this breakthrough might eventually lead to improved vaccines, or even better treatments, for smallpox itself, a disease that remains a serious concern due to its contagiousness and high mortality.
The team’s ongoing work focuses on refining these viral proteins and antibodies to make them more potent, less costly, and easier to produce than current options, which involve working with weakened poxviruses. Their ultimate goal is to test these innovative vaccines and treatments in human trials, advancing what McLellan calls a “reverse vaccinology” approach — starting from human immune responses and working backward to engineer better defenses.
To protect their inventions, UT Austin has filed a patent application for the use of OPG153 and related molecules as vaccine antigens. Similarly, the Italian researchers have secured a patent for the antibodies targeting this protein. Several other scientists and contributors from UT Austin, including Emily Rundlet, Ling Zhou, and Connor Mullins, have also played vital roles.
Funding support for this groundbreaking research was partially provided by the Welch Foundation.
This discovery isn’t just about monkeypox; it challenges traditional vaccine development methods and raises important questions: Could AI revolutionize how we combat other infectious diseases by identifying novel viral targets? And might this approach shift the landscape of vaccine design, making it faster, cheaper, and more precise? What do you think about relying on AI in critical health breakthroughs — a game-changer or a risky shortcut? Share your thoughts below—these discussions could shape the future of medical innovation.
